Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
-
Krystal Biotech (KRYS) PT Raised to $140 at Chardan Capital Markets, Following Clinical Business Update
-
Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference
-
Krystal Biotech (KRYS) Selected as a 'Top Pick' for 2021 by Chardan Capital, Sees 3-4 Major Catalysts
-
Krystal Biotech to Present at Upcoming Investor Conferences
-
UPDATE: Krystal Biotech (KRYS) Prices 2.275M Share Common Offering at $55/Sh
-
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock
-
Krystal Biotech (KRYS) PT Raised to $100 at Chardan Capital Markets
-
Krystal Biotech (KRYS) PT Raised to $90 at Chardan Capital Markets
-
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference
-
Krystal Biotech (KRYS) Prices 2.5M Share Common Offering at $40/Sh
-
Krystal Biotech Announces Pricing of $100.0 Million Public Offering of Common Stock
-
Krystal Biotech (KRYS) PT Raised to $75 at Chardan Capital Markets
-
Krystal Biotech (KRYS) PT Raised to $57.50 at Chardan Capital Markets
-
Krystal Biotech Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option
-
Chardan Serves as Lead Manager for Krystal Biotech
-
Krystal Biotech (KRYS) Prices 3M Share Offering at $20/Sh
-
Krystal Biotech Announces Pricing of $60.0 Million Public Offering of Common Stock
-
Krystal Biotech (KRYS) Commences $60M Public Offering of Common Stoc
-
Krystal Biotech Announces Commencement of $60.0 Million Public Offering of Common Stock
-
Krystal Biotech (KRYS) PT Raised to $50 at Chardan Capital Markets
-
Krystal Biotech to Present at Chardan Annual Genetic Medicines Conference
-
Chardan Capital Markets acts as Sole Placement Agent in $10 Million Securities Purchase
-
Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners
-
Chardan Capital Markets Starts Krystal Biotech (KRYS) at Buy

